Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological effects and imaging of bevacizumab in surgically resectable melanoma
NL-OMON30987Phase 2Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in melanoma and cutaneous malignancy, sponsored by University Medical Center Groningen. Primary endpoints: Safety, Biological parameters and 2 more. Planned start May 2007; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON30987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30987.